India to Burkina Faso Pharmaceutical Export (2026) — $65.6M, 118 Suppliers | TransData Nexus

India to Burkina Faso Pharmaceutical Export (2026) — $65.6M, 118 Suppliers | TransData Nexus | TransData Nexus

Top Pharmaceutical Formulations — India to Burkina Faso

#	Formulation	Value	Share
1	Paracetamol Tablets BP 500mg Qty: 23400x	$33.0M	50.3%
2	H/m - Amodiaquine 150mg+sulfadoxine/pyrimethamine 500/25mg Dispersible Tablets…	$2.4M	3.7%
3	Harm Medi-amodiaquine 150mg +sulfadoxine/pyrimethamine 500/25mg Dispersible Tab…	$1.9M	2.9%
4	Harmless Medicines:amodiaquine 150mg +sulfadoxine/pyrimethamine 500/25mg Disper…	$1.6M	2.4%
5	Dtp-hepb-hib (pentavalent Vaccine) Fully	$1.2M	1.8%
6	Amoxicillin Capsules BP 500mg Qty 12000 X 100 X 10s	$733.6K	1.1%
7	Dtp-hepb-hib (pentavalent Vaccine) Fullyliquid Combination Vaccine 10 Dose Vial…	$657.9K	1.0%
8	Tenofovirdisoproxilfumarate300mg+	$641.9K	1.0%
9	Artesunate 60mg Powder for Injection	$564.4K	0.9%
10	H/m-amodiaquine 75mg+sulfadoxine/pyrimethamine 250/12.5mg Dispersible Tablets U…	$496.8K	0.8%
11	Dtp-hepb-hib (pentavalent Vaccine) Fullyliquid Combination Vaccine, 10 Dose (5m…	$474.6K	0.7%
12	S359348 Mr Vaccine Measles and Rubella	$472.6K	0.7%
13	Harmless Medicine - Amodiaquine 75mg+sulfadoxine/pyrimethamine 250/12.5 MG Disp…	$449.7K	0.7%
14	Tablet Phloroglucinol 80mg. Each Tabletcontains:phloroglucinol 80mg B.no.eht241…	$406.4K	0.6%
15	Enoxaparin Sodium Injection USP (40 MG /0.4 Ml), Bt No#p01h159 to P01h163 ,md#0…	$320.0K	0.5%

India exports 20+ pharmaceutical formulations to Burkina Faso with a combined trade value of $65.6M. Key products include Paracetamol ($33.0M), Amoxicillin ($734K), Artesunate ($564K), Vaccine ($473K), Enoxaparin ($320K). These are finished dosage forms — tablets, capsules, injectables, and combination drugs — shipped from Indian manufacturing facilities with FDA, WHO-GMP, and EU GMP certifications. Data from 2,692 verified Indian Customs (DGFT) shipment records.

Top Pharmaceutical Products — India to Burkina Faso Trade Routes

1Paracetamol$33.0M

2Amoxicillin$734K

3Artesunate$564K

4Vaccine$473K

5Enoxaparin$320K

Top Indian Exporters to Burkina Faso

1Fourrts (india) Laboratories Private Limited

$36.4M

2S Kant Healthcare Limited

$7.0M

3Sidhaant Life Sciences Private Limited

$5.8M

4Biological E. Limited

$2.6M

Port Analysis — India to Burkina Faso Pharmaceutical Shipments

Indian Export Ports

KAMARAJAR PORT0.4%

NHAVA SHEVA0.8%

KAMARAJAR PORT (INENR1)2.4%

PATLI ICD (INPTL6)1.6%

NHAVA SHEVA SEA (INNSA1)7.3%

Burkina Faso Import Ports

Abidjan1.5%

Ouagadougou14.4%

OUAGADOUGOU76.4%

ABIDJAN0.5%

Lome0.4%

Trade Statistics

Total Value$65.6M

Shipments2,692

Indian Exporters118

Burkina Faso Buyers150

Avg Shipment$24K

Products2,200

Other Destinations

United States$8.8B United Kingdom$1.2B Canada$1.1B

Last updated: March 28, 2026

India–Burkina Faso Pharmaceutical Trade Corridor Analysis

Historical evolution, India's market position, and recent developments

1Trade Corridor Evolution

The pharmaceutical trade between India and Burkina Faso has experienced significant growth over the past decade. In 2024, India's pharmaceutical exports to Burkina Faso reached $46.57 million, marking a substantial increase from previous years. This surge underscores the strengthening bilateral trade relations and India's growing role in supplying essential medicines to Burkina Faso.

A pivotal milestone occurred in July 2025, when India and Burkina Faso signed a $50 billion agreement to establish Africa's first large-scale pharmaceutical industry. This landmark deal aims to enhance local production capabilities, reduce dependency on imports, and improve access to affordable medications across the region. The collaboration is expected to create a robust pharmaceutical manufacturing hub, positioning Burkina Faso as a key player in Africa's healthcare sector.

2India's Market Position

India holds a dominant position in Burkina Faso's pharmaceutical import market. In 2024, India's pharmaceutical exports to Burkina Faso amounted to $46.57 million, accounting for approximately 17.2% of Burkina Faso's total pharmaceutical imports, which stood at $270.18 million. This substantial share highlights India's strategic importance as a primary supplier of essential medicines to Burkina Faso.

The establishment of a large-scale pharmaceutical manufacturing facility in Burkina Faso further solidifies India's market position. By investing in local production, India not only strengthens its trade ties but also contributes to the economic development and healthcare improvement of Burkina Faso.

Product Categories & Therapeutic Trends — India to Burkina Faso

Dominant categories, emerging opportunities, and demand drivers

1Dominant Categories

India's pharmaceutical exports to Burkina Faso are predominantly concentrated in the antimalarial and analgesic therapeutic categories. The leading product, Paracetamol Tablets BP 500mg, accounts for 50.3% of the total export value, underscoring the significant demand for pain relief medications. Additionally, the combination of Amodiaquine 150mg and Sulfadoxine/Pyrimethamine 500/25mg Dispersible Tablets, marketed as Supyra Dispersible, represents 8.9% of the export value, highlighting the critical need for antimalarial treatments.

These therapeutic areas align with Burkina Faso's healthcare priorities, where malaria remains a major public health challenge. The World Health Organization (WHO) reports that malaria continues to be a leading cause of morbidity and mortality in the country, necessitating effective prevention and treatment strategies. The substantial export of antimalarial drugs from India to Burkina Faso reflects the ongoing efforts to combat this pervasive disease. (healthcluster.who.int)

2Emerging Opportunities

The pharmaceutical landscape in Burkina Faso presents emerging opportunities for Indian exporters, particularly in the realm of biosimilars and the management of non-communicable diseases (NCDs). The WHO's Biennial Report for 2024–2025 highlights the adoption of the WHO PEN package in six districts, aiming to strengthen the management of NCDs through integrated primary health care services. This initiative indicates a growing focus on chronic disease management, creating a potential market for biosimilars and other treatments for conditions such as hypertension and diabetes. (afro.who.int)

Furthermore, the global trend of patent expirations, known as the "patent cliff," is creating opportunities for Indian generic pharmaceutical companies to enter markets like Burkina Faso. As patents for various medications expire, there is an increased demand for affordable generic alternatives, which Indian manufacturers are well-positioned to supply.

3Demand Drivers

Burkina Faso's disease burden, characterized by a high prevalence of infectious diseases such as malaria and emerging non-communicable diseases, significantly drives the demand for pharmaceutical imports. The WHO reports that nearly 31% of health facilities are affected by insecurity, with 17.7% completely closed, compromising essential services like vaccination and emergency care. This situation exacerbates the need for reliable pharmaceutical supplies to address both acute and chronic health conditions. (healthcluster.who.int)

Additionally, the country's healthcare spending per capita was $56.76 in 2022, reflecting a slight decline from the previous year. This indicates financial constraints that may limit domestic production capabilities, thereby increasing reliance on imports to meet the population's healthcare needs.

In summary, India's pharmaceutical exports to Burkina Faso are primarily driven by the need for antimalarial and analgesic medications, with emerging opportunities in biosimilars and generic drugs. The country's disease burden and healthcare spending trends further underscore the demand for pharmaceutical imports to address both infectious and chronic health challenges.

TransData Nexus Research · DGFT trade data analysisMar 2026

Trade Policy & Tariff Intelligence — India and Burkina Faso

Tariff structure, trade agreements, IP and patent landscape

1Tariff & Duty Structure

Burkina Faso, as a member of the West African Economic and Monetary Union (WAEMU), adheres to the Common External Tariff (CET) established by the union. This CET standardizes import duties across member states, including Burkina Faso, to promote regional integration and economic cohesion. While specific MFN (Most Favored Nation) tariff rates for pharmaceutical products under HS codes 3003 and 3004 are not publicly detailed, the CET typically imposes import duties on pharmaceutical products, with rates varying based on the product's nature and intended use. For instance, medicaments containing vitamins or other products of heading 29.36 may attract duties ranging from 0% to 15%, depending on specific formulations and classifications. (customs.gov.bz)

Regarding preferential duty rates, Burkina Faso's participation in WAEMU allows for reduced or zero-duty imports from other member states. However, as Burkina Faso does not have a Free Trade Agreement (FTA) with India, pharmaceutical imports from India would be subject to the standard CET rates without preferential treatment.

2Trade Agreements

Burkina Faso is a member of WAEMU, which facilitates trade among member countries through a unified external tariff system. However, Burkina Faso does not have a Free Trade Agreement (FTA) with India. Consequently, pharmaceutical imports from India are subject to the standard Common External Tariff (CET) rates without preferential treatment.

3IP & Patent Landscape

Burkina Faso's intellectual property (IP) framework, including patent provisions, is influenced by its membership in the African Intellectual Property Organization (OAPI). OAPI's regulations govern patent rights, data exclusivity, and compulsory licensing across member states. These provisions can impact the entry of generic drugs into the market, potentially affecting the competitiveness of Indian pharmaceutical exports. However, specific details regarding the application of these IP provisions to Indian generic drugs in Burkina Faso are not readily available.

TransData Nexus Research · Trade policy databasesMar 2026

Supply Chain & Logistics — India to Burkina Faso Pharma Shipments

Shipping routes, port infrastructure, cold chain compliance

1Shipping Routes & Transit

Pharmaceutical shipments from India to Burkina Faso predominantly utilize sea freight due to cost-effectiveness for large volumes. The primary sea route involves transporting goods from Indian ports to major West African ports such as Abidjan (Ivory Coast), Tema (Ghana), and Cotonou (Benin). From these ports, cargo is typically moved inland to Burkina Faso via road or rail. For instance, shipments arriving at Abidjan may be transported to Ouagadougou, the capital of Burkina Faso, while those arriving at Tema or Cotonou are often routed to Bobo Dioulasso, the country's second-largest city.

Air freight is less commonly used due to higher costs but is preferred for urgent deliveries. Air shipments generally arrive at Ouagadougou International Airport, facilitating direct access to the capital. Transit times vary based on the specific route and mode of transport. Sea freight from Indian ports to West African ports typically takes several weeks, depending on the specific ports and shipping schedules. Inland transportation from these ports to Burkina Faso adds additional time, with road transport taking several days to a week. Air freight offers faster delivery, with transit times ranging from a few days to a week, depending on the specific route and logistics arrangements.

Recent disruptions in the Red Sea have had minimal impact on this trade corridor, as the primary shipping routes for India to Burkina Faso do not pass through the Red Sea. Therefore, alternative routes via the Atlantic Ocean remain unaffected, ensuring continuity in pharmaceutical shipments.

2Port Infrastructure

In India, key export ports handling pharmaceutical shipments include Kamarajar Port, Nhava Sheva, and Visakhapatnam Port. Kamarajar Port, located in Tamil Nadu, is a significant hub for containerized cargo. Nhava Sheva, also known as Jawaharlal Nehru Port, is the largest container port in India, handling a substantial volume of pharmaceutical exports. Visakhapatnam Port, situated in Andhra Pradesh, serves as a crucial gateway for exports from the eastern region.

In Burkina Faso, Ouagadougou International Airport serves as the primary import port for pharmaceutical products, facilitating air freight deliveries directly to the capital. For sea freight, goods are typically routed through neighboring ports such as Abidjan, Tema, and Cotonou, with subsequent inland transportation to destinations within Burkina Faso.

3Cold Chain & Compliance

Temperature-sensitive pharmaceutical formulations, including vaccines and biologics, require strict cold chain management to maintain efficacy. The World Health Organization (WHO) provides guidelines for the storage and transport of time- and temperature-sensitive pharmaceutical products, emphasizing the need for controlled environments throughout the supply chain. (who.int)

In compliance with these standards, shipments from India to Burkina Faso must ensure that products are stored and transported within specified temperature ranges, typically between 2°C and 8°C. This involves using validated cold chain containers equipped with temperature monitoring devices to track and record conditions during transit. Additionally, packaging materials should be of commercial standard, providing adequate protection against adverse climatic and storage conditions, including high humidity. (cdn.who.int)

Adhering to Good Distribution Practices (GDP) is essential to ensure product quality and compliance with regulatory requirements. This includes securing shipments to prevent unauthorized access, maintaining appropriate environmental conditions, and ensuring that packaging features are intact upon arrival. (who.int)

TransData Nexus Research · DGFT port data, shipping intelligenceMar 2026

Market Opportunity Assessment — Burkina Faso for Indian Pharma

Market size, healthcare system, growth outlook

1Market Size & Growth

Burkina Faso's pharmaceutical market is projected to reach a revenue of US$130.12 million by 2025, with an anticipated annual growth rate of 3.72% from 2025 to 2030, leading to a market volume of US$156.20 million by 2030. This growth is driven by increasing healthcare needs and government initiatives aimed at improving access to essential medicines.

The country's health expenditure stands at 5.46% of its GDP, reflecting a commitment to healthcare investment. The generic drug penetration rate is significant, as evidenced by the government's recent decision to reduce prices of essential generic medicines by up to 72.73% to enhance affordability and access.

2Healthcare System

Burkina Faso has implemented several health financing reforms aimed at fostering progress towards Universal Health Coverage (UHC), with a particular focus on maternal and child care. The government has also allocated 3 billion CFA francs (approximately US$5.4 million) to reduce the prices of essential generic medicines and medical supplies, aiming to alleviate the financial burden on households and improve access to treatment.

3Opportunity for Indian Exporters

Indian pharmaceutical exporters have a substantial opportunity in Burkina Faso, particularly in the generic drug segment. The government's focus on reducing prices of essential generic medicines aligns with India's strength in producing cost-effective generic drugs. With a total export value of US$65.6 million in finished pharmaceutical formulations, India has established a strong presence in the market. The top 10 products exported include paracetamol tablets, amodiaquine-sulfadoxine-pyrimethamine combinations, and pentavalent vaccines, indicating a demand for both essential and specialized medications. The market's projected growth and the government's supportive policies present a favorable environment for Indian exporters to expand their footprint in Burkina Faso.

TransData Nexus Research · Burkina Faso healthcare dataMar 2026

Competitive Landscape — India vs Other Pharmaceutical Suppliers to Burkina Faso

Competing origins, India's edge, challenges and threats

1Competing Origins

Burkina Faso's pharmaceutical market is characterized by a diverse array of suppliers, including China, European Union (EU) manufacturers, domestic producers, and other emerging markets. China and EU countries have historically been significant exporters to Burkina Faso, providing a range of pharmaceutical products. For instance, in 2024, Ghana exported approximately $3.77 million worth of pharmaceutical products to Burkina Faso, indicating a competitive presence in the region.

Domestic production in Burkina Faso focuses primarily on essential medicines such as antimalarials, antibiotics, painkillers, rehydration salts, and saline solutions. However, the local manufacturing capacity remains limited, leading to a heavy reliance on imports to meet the country's pharmaceutical needs.

Other emerging markets, including India, have also established a foothold in supplying pharmaceuticals to Burkina Faso. In 2024, India exported approximately $65.6 million worth of pharmaceutical products to the country, with a total of 2,692 shipments from 118 Indian exporters. This substantial export volume underscores India's growing presence in the Burkinabe pharmaceutical market.

2India's Competitive Edge

India's pharmaceutical industry offers several competitive advantages in the Burkina Faso market. The country's cost competitiveness is a significant factor, as Indian manufacturers can provide affordable generic drugs, which aligns with Burkina Faso's preference for cost-effective medications. Additionally, India's adherence to WHO-GMP standards ensures that products meet international quality benchmarks, enhancing their appeal in the Burkinabe market. The widespread use of English in India facilitates smoother communication and business transactions with international partners. Furthermore, India's broad portfolio of pharmaceutical products, including essential medicines and specialized treatments, caters to the diverse healthcare needs of Burkina Faso.

3Challenges & Threats

Despite its advantages, India's pharmaceutical exports to Burkina Faso face several challenges. Regulatory tightening by Burkina Faso's National Drug Regulatory Authority (WHO-GMP) may impose stricter compliance requirements, potentially affecting the ease of market entry for Indian exporters. Intensifying competition from China, which offers a wide range of pharmaceutical products at competitive prices, poses a threat to India's market share. Additionally, perceptions regarding the quality of Indian pharmaceuticals may vary, and addressing these perceptions is crucial for maintaining and expanding India's presence in the Burkinabe market.

TransData Nexus Research · Global trade databasesMar 2026

FAQ — India to Burkina Faso Pharmaceutical Trade

What is the total value of India's pharmaceutical export to Burkina Faso?

India exported pharmaceuticals worth $65.6M to Burkina Faso across 2,692 verified shipments.

Who are the top Indian pharmaceutical exporters to Burkina Faso?

1. FOURRTS (INDIA) LABORATORIES PRIVATE LIMITED — $36.4M. 2. S KANT HEALTHCARE LIMITED — $7.0M. 3. SIDHAANT LIFE SCIENCES PRIVATE LIMITED — $5.8M. Total: 118 suppliers.

Which companies in Burkina Faso import pharmaceuticals from India?

1. CAMEG — $43.9M. 2. TO THE ORDER — $9.8M. 3. MINISTERE DE LA SANTE — $1.3M. 150 buyers total.

What pharmaceutical products does India export most to Burkina Faso?

1. Paracetamol Tablets BP 500mg Qty: 23400x ($33.0M, 50.3%); 2. H/m - Amodiaquine 150mg+sulfadoxine/pyrimethamine 500/25mg Dispersible Tablets… ($2.4M, 3.7%); 3. Harm Medi-amodiaquine 150mg +sulfadoxine/pyrimethamine 500/25mg Dispersible Tab… ($1.9M, 2.9%); 4. Harmless Medicines:amodiaquine 150mg +sulfadoxine/pyrimethamine 500/25mg Disper… ($1.6M, 2.4%); 5. Dtp-hepb-hib (pentavalent Vaccine) Fully ($1.2M, 1.8%)

Which ports handle pharmaceutical shipments from India to Burkina Faso?

Export: KAMARAJAR PORT, NHAVA SHEVA, KAMARAJAR PORT (INENR1), PATLI ICD (INPTL6), NHAVA SHEVA SEA (INNSA1). Import: Abidjan, Ouagadougou, OUAGADOUGOU, ABIDJAN, Lome.

Why does Burkina Faso import pharmaceuticals from India?

India's cost-competitive generic drug manufacturing, WHO-GMP certified facilities, and broad product portfolio. This $65.6M corridor reflects quality compliance and pricing advantages.

What certifications do Indian pharmaceutical exporters need to supply Burkina Faso?

WHO-GMP certification, EU GMP approval (for EU markets), product dossier registration (CTD format), and ICH guideline compliance.

What is the average shipment value for India to Burkina Faso pharmaceutical trade?

$24.4K per consignment across 2,692 shipments.

How many Indian pharmaceutical companies export to Burkina Faso?

118 Indian companies. Largest: FOURRTS (INDIA) LABORATORIES PRIVATE LIMITED with $36.4M.

How can I find verified Indian pharmaceutical suppliers for Burkina Faso?

TransData Nexus covers 118 active exporters with shipment history and trade values at transdatanexus.com.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Data Source: Indian Customs (DGFT) export shipping bill records covering all pharmaceutical shipments from India.
2.Country Matching: Shipments to Burkina Faso identified using destination country codes from customs declarations.
3.Statistical Normalization: Values are statistically normalized to remove outlier transactions and ensure accurate market share representation.
4.Coverage: 2,692 verified shipments from 118 Indian exporters to 150 Burkina Faso buyers.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

118 Exporters

150 buyers tracked

Expert-Reviewed

By pharmaceutical trade specialists

India to Burkina Faso Pharmaceutical Export